Drugs Made In America Acquisition II Corp. (DMII) Form 10-K Annual Reports
Drugs Made In America Acquisition II Corp. (DMII) is a publicly traded company on the Nasdaq, categorized under SIC 6770 (Blank Checks). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: DMII
CIK: 2040475
Exchange: Nasdaq
SIC 6770: Blank Checks
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
MaloneBailey, LLP
Auditor SinceSince 12/31/2024 12:00:00 AM
Lead Engagement PartnerGeorge Qin
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-090017 | View SEC Doc Filr Page |
| 10-Q | 2026-05-14 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-056651 | View SEC Doc Filr Page |
| 8-K | 2026-04-28 | 2026-04-22 | CURRENT REPORT | 0001213900-26-048687 | View SEC Doc Filr Page |
| 10-K | 2026-04-15 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-044055 | View SEC Doc Filr Page |
| 8-K | 2026-04-03 | 2026-03-24 | CURRENT REPORT | 0001213900-26-039986 | View SEC Doc Filr Page |
| NT 10-K | 2026-04-01 | 2025-12-31 | NOTIFICATION OF LATE FILING | 0001213900-26-038498 | View SEC Doc Filr Page |
| 8-K | 2026-03-17 | 2026-03-11 | CURRENT REPORT | 0001213900-26-029050 | View SEC Doc Filr Page |
| 8-K | 2026-03-06 | 2026-03-06 | FORM 8-K | 0001213900-26-024763 | View SEC Doc Filr Page |
| 8-K | 2026-03-06 | 2026-02-28 | CURRENT REPORT | 0001213900-26-024387 | View SEC Doc Filr Page |
| 10-Q | 2025-11-18 | 2025-09-30 | QUARTERLY REPORT | 0001213900-25-112095 | View SEC Doc Filr Page |
| 8-K | 2025-11-18 | 2025-10-08 | CURRENT REPORT | 0001213900-25-111706 | View SEC Doc Filr Page |
| NT 10-Q | 2025-11-17 | 2025-09-30 | NOTIFICATION OF LATE FILING | 0001213900-25-111209 | View SEC Doc Filr Page |
| 4 | 2025-10-17 | 2025-09-26 | 4 Filing | 0001213900-25-099838 | View SEC Doc Filr Page |
| 8-K | 2025-10-02 | 2025-09-26 | CURRENT REPORT | 0001213900-25-095513 | View SEC Doc Filr Page |
| 4 | 2025-10-02 | 2025-09-26 | 4 Filing | 0001213900-25-095291 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2025-10-02 | — | SCHEDULE 13D Filing | 0001213900-25-094944 | View SEC Doc Filr Page |
| 4 | 2025-10-01 | 2025-09-26 | 4 Filing | 0001213900-25-094676 | View SEC Doc Filr Page |
| 4 | 2025-10-01 | 2025-09-26 | 4 Filing | 0001213900-25-094436 | View SEC Doc Filr Page |
| 4 | 2025-10-01 | 2025-09-26 | 4 Filing | 0001213900-25-094430 | View SEC Doc Filr Page |
| 4 | 2025-10-01 | 2025-09-26 | 4 Filing | 0001213900-25-094427 | View SEC Doc Filr Page |
| 8-K | 2025-09-29 | 2025-09-24 | CURRENT REPORT | 0001213900-25-093224 | View SEC Doc Filr Page |
| 3 | 2025-09-25 | 2025-09-24 | 3 Filing | 0001213900-25-091842 | View SEC Doc Filr Page |
| 424B4 | 2025-09-25 | — | PROSPECTUS SUPPLEMENT | 0001213900-25-091724 | View SEC Doc Filr Page |
| EFFECT | 2025-09-24 | — | EFFECT Filing | 9999999995-25-003076 | View SEC Doc Filr Page |
| 3 | 2025-09-24 | 2025-09-24 | 3 Filing | 0001213900-25-091255 | View SEC Doc Filr Page |